SOURCE: The Hydropothecary Corporation

medical marijuana thcx thc hydropothecary

November 02, 2017 16:33 ET

Hydropothecary Announces Bought Deal Offering to be Extended to Quebec

GATINEAU, QC--(Marketwired - November 02, 2017) - The Hydropothecary Corporation (TSX VENTURE: THCX)

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Hydropothecary Corporation ("THCX" or the "Company") (TSX VENTURE: THCX) announced today that its previously announced bought deal offering of 60,000 convertible debenture units of the Company for aggregate gross proceeds of $60,000,000 will be extended to include the Province of Québec. Accordingly, the units will be offered and sold by way of a bought deal public offering in all provinces and territories of Canada and the Company will file a short form prospectus qualifying the issuance of the units in all provinces and territories of Canada pursuant to National Instrument 44-101 - Short Form Prospectus Distributions.

The offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides sungrown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with Hydropothecary's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • For Investor Relations Inquiries:
    Jennifer Smith
    Manager of Financial Reporting and Investor Relations
    1-866-438-THCX (8429)
    invest@THCX.com
    www.THCX.com

    For Media Inquiries:
    Julie Beun
    Publicist and Media Relations
    julie@thehydropothecary.com
    613-371-9060
    or
    Adam Miron
    Director
    819-639-5498